Leukemia section

Leukemia News and Features

New tool uses drug spillover to match cancer patients with treatments

A new tool predicts what genetics are truly driving the cancer in any population of cells and helps the user choose the best kinase inhibitor to address the issue.

In refractory leukemia, IV busulfan plus cyclophosphamide may be a valid alternative

In refractory leukemia, IV busulfan plus cyclophosphamide may be a valid alternative

Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative for patients with refractory acute myeloid leukemia.

Patient-reported resilience associated with outcomes after HCT

Patient-reported resilience associated with outcomes after HCT

Among long-term survivors of hematopoetic cell transplantation (HCT), patient-reported resilience is independently associated with outcomes.

Expensive new leukemia medication to be covered by Medicare

Expensive new leukemia medication to be covered by Medicare

Amgen's Blincyto costs about 178,000 for a standard course of treatment.

Research breakthrough identifies how mutated genes reprogram blood stem cells in leukemia

Research breakthrough identifies how mutated genes reprogram blood stem cells in leukemia

You research has shed light on the process by which mutated genes in leukemia reprogram blood stem cells and send them spiraling out of control.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs